DEDHAM, Mass. — An engineer who analyzes crash data was called to the stand Friday in the Karen Read retrial as the defense began presenting its case.. Prosecutors rested their case on Thursday ...

A controversial company that sells license plate readers has developed a new surveillance tool that pulls together disparate datasets and connects them to drivers’ car information.

Witness Jessica Hyde, a digital forensic data analyst, talks about data on Jennifer McCabe's cell phone during the Karen Read murder trial at Norfolk Superior Court in Dedham, Mass ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are tumbling on Tuesday. The stock lost 10.3% as of 2:50 p.m. ET and was down by as much as 11.8% earlier in the day. The move comes as the S&P ...

Recursion will present preliminary safety and efficacy data for REC-4881 in familial adenomatous polyposis at DDW 2025. Quiver AI Summary. Recursion, a clinical-stage TechBio company, is set to ...

Using Chunk to process large files in C# Chunking is beneficial whenever you’re handling large data sets or massive volumes of data. Chunking also comes in handy when processing large files ...

The Data Science Lab. Decision Tree Regression from Scratch Using C#. Dr. James McCaffrey from Microsoft Research presents a complete end-to-end demonstration of decision tree regression using the C# ...

Recursion states that REC-1245 is the first program using the company’s end-to-end AI platform, spanning discovery, biology, chemistry, and the clinic.

Recursion posts mid-stage data for lead asset Sep. 03, 2024 8:43 AM ET Recursion Pharmaceuticals, Inc. (RXRX) Stock By: Dulan Lokuwithana , SA News Editor 3 Comments Play ( 1min ) ...

Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that, while a success on paper, likely won’t satisfy many investors closely watching the AI ...

Nvidia-backed Recursion Pharmaceuticals said on Tuesday its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid-stage study, but showed mixed results for ...